Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009
J Clin Oncol. 2025 Nov 10:JCO2501357. doi: 10.1200/JCO-25-01357. Online ahead of print. ABSTRACT PURPOSE: Modern ALL therapy aims to reduce toxicity, while maintaining and improving …